Affidea expands in Romania through the acquisition of CT Clinic

Affidea, the leading European provider of diagnostic imaging, outpatient and cancer care services has today announced the acquisition of CT Clinic, an important medical provider of PET/CT examinations, located in Cluj-Napoca. This latest investment strengthens Affidea’s presence in oncology market by adding the third PET/CT center to its local network, in this way increasing the access to oncological patients to high quality examinations for advanced diagnostic and monitoring of the disease.

CT-Clinic is a well-known PET/CT center located in Cluj Napoca, covering a catchment area of 2.6m inhabitants – approximately 13% of Romania’s population. The center is EARL accredited for their medical expertise in PET/CT examinations. Moreover, CT Clinic  has a unique know-how in PET/CT scans for prostate cancer, using a special tracer F18- fluorocholine (FCH), which offers a high accuracy in the diagnostic and monitoring of this disease.

With this acquisition, Affidea grows its country network to 37 centers. Affidea Romania currently performs almost 1,6 m examinations of diagnostic imaging and PET/CT, benefitting from the expertise of more than 1000 dedicated health professionals. In Romania, Affidea offers patients PET/CT examinations, both private and reimbursed by NHS, in three locations: The Excellence Center in Oncology Affidea Fundeni Bucharest, Affidea Timisoara and CT Clinic Cluj.

Mesut Goral, Senior VicePresident Affidea CEE Region and Country Manager Interim Romania, stated: „CT Clinic acquisition proves our commitment to cancer care, offering a wider and more integrated access to high quality medical care for Romanian oncological patients. We have a successful legacy into the PET/CT market, built over the last 18 years and we are recognised as the expert in this area, so the addition of CT Clinic complements very well our portfolio of services. We look forward to working with CT Clinic team and I am convinced that the experience and assets of both teams will capture the great opportunities ahead, delivering value to all our stakeholders, starting from the patient, the referring physician and the national health system.” 

Commenting on the acquisition, Dr. Titus Bogdan Spataru, Deputy General Manager of CT Clinic, added: „Since 2013, we have placed a great focus on delivering high quality medical examinations, with an experienced clinical team and always bringing the latest technology, offering to our patients the best possible care. Now the company is ready for its new chapter to further grow with the support of a reputed pan-European player. The entry in such Affidea’s network will allow CT Clinic to have a bright future with an international outlook”.

About PET/CT Examination

PET/CT is an advanced nuclear medicine examination that helps clinicians determine the location of the primary lesion of cancer and assists cancer staging and the assessment of recurrence of the disease. The investigation can also help assess the effectiveness of the treatment, the patient’s individual response to a therapeutic method used, e.g. chemotherapy, and guide clinicians towards the further process of patient’s treatment in oncology and radiotherapy planning.